Prosecution Insights
Last updated: November 20, 2026
Application No. 18/953,295

Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity

Non-Final OA §103§112§DOUBLEPATENT
Filed
Nov 20, 2024
Priority
Nov 04, 2015 — provisional 62/250,575 +4 more
Examiner
GONZALEZ, LUISALBERTO
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Merck Patent GmbH
OA Round
1 (Non-Final)
58%
Grant Probability
Moderate
1-2
OA Rounds
11m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 58% of resolved cases
58%
Career Allowance Rate
98 granted / 168 resolved
-1.7% vs TC avg
Strong +48% interview lift
Without
With
+47.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
64 currently pending
Career history
236
Total Applications
across all art units

Statute-Specific Performance

§101
2.8%
-37.2% vs TC avg
§103
38.0%
-2.0% vs TC avg
§102
13.2%
-26.8% vs TC avg
§112
31.0%
-9.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 168 resolved cases

Office Action

§103 §112 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Filing Receipt and Priority The filing receipt mailed 02/11/2025 states that the instant application is a continuation of 17/232,383, filed 04/16/2021, which is a continuation 15/343,570, filed 11/04/2016, which claims benefit of provisional applications 62/341,189, filed 05/25/2016, 62/296,143, filed 02/17/2026, and 62/250,575 filed 11/04/2015. The provisional application 62/250,575 supports the instant claims. Therefore the effective filing date is 11/04/2016. Information Disclosure Statement The information disclosure statements submitted 11/20/2024 and 10/23/2026 have been considered. Objection Claims 17 states “effective amount eliminates is an amount that eliminates”. Rejections Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-20 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 states “A method of treating acute myeloid leukemia in a human subject, comprising….”. The term “human subject” is not defined within the specification or claim. The broadest reasonable interpretation is any and all human subjects, including those who do not have the condition. Without an explicit definition and because the claim also does not make the subject explicit, the claim is indefinite as one of ordinary skill does not know the metes and bounds of the claim. This rejection can be overcome if applicant amends in the term “in need thereof” to describe “human subject” or if language stating that the “human subject” has acute myeloid leukemia is added. As claims 2-20 are dependent on claim 1, they are also rejected. Claim 20 states “The method of claim 1, wherein the treatment achieves a normal level of cell proliferation.” The term “normal level of cell proliferation” is indefinite because “normal” is not defined within the specification or claim and the specification does not teach how one of ordinary skill in the art would determine which levels of cell proliferation are normal or not normal. Essentially, “normal” is a relative term and the claim is indefinite. Further, “cell proliferation” is indefinite because the type of cell is not specified. While the claim is dependent upon claim 1, which is drawn to a method of treating acute myeloid leukemia, the specification, regarding cell proliferation, only states it In regards to kinases (p. 2, l. 8), BTK pathways (p. 3, l. 4), and “abnormal cell proliferation” (p. 41, l. 23). Critically, the specification on p. 3 states “BTK plays important roles in the development, differentiation, activation and proliferation of B cells, as well as their antibody and cytokine generation.” As the claim does not specify which cell type is returned to “normal” proliferation, the claim is indefinite as one of ordinary skill would not know the metes and bounds of the claim. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. KSR Rationales The MPEP in section 2143, subsection I gives examples of Rationales for supporting a conclusion of obvious. These rationales are non-exhaustive and include (A) Combining prior art elements according to known methods to yield predictable results; (B) Simple substitution of one known element for another to obtain predictable results; (C) Use of known technique to improve similar devices (methods, or products) in the same way; (D) Applying a known technique to a known device (method, or product) ready for improvement to yield predictable results; (E) “Obvious to try” – choosing from a finite number of identified, predictable solutions, with a reasonable expectation of success; (F) Known work in one field of endeavor may prompt variations of it for use in either the same field or a different one based on design incentives or other market forces if the variations are predictable to one of ordinary skill in the art; (G) Some teaching, suggestion, or motivation in the prior art that would have led one of ordinary skill to modify the prior art reference or to combine prior art reference teachings to arrive at the claimed invention. Claim(s) 1-20 is/are rejected under 35 U.S.C. 103 as being unpatentable over Hodous (WO2012/170976, of the record) in view of Rushworth (Blood, 2014, Vol. 123, No 8). Hodous on p. 170, l. 13-21 teaches compound A225, shown below, and its synthesis. Regarding claims 1 and 2, Compound A225 has the IUPAC name 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)-4-fluoropiperidin-1-yl)prop-2-en-1-one. This is the same compound as claimed in the method of instant claim 1. PNG media_image1.png 396 570 media_image1.png Greyscale Hodous on p. 235, Table 1 teaches compound A225’s efficacy as a BTK inhibitor, which is listed as “A” which is indicated as “<100nM” (p. 228, l. 27). Hodous on p. 24 l. 30-24 contemplates treatment of leukemia. Further, Hodous on p. 41, l. 27- p. 42, l. 35 contemplates cancers to be treated, including acute myeloid leukemia. Regarding claim 3, Hodous on p. 23, l. 7- p. 24, l. 3 contemplates pharmaceutically acceptable salts. Regarding claims 4-5, and 15, Hodous on p. 24, l. 22-26 contemplates a pharmaceutical composition designed for oral administration. Pharmaceutical carriers are discussed on p. 25, l. 5-8. Regarding claims 6-13 and claims 18-19, Hodous on p. 30, l. 4-12 contemplates doses and dose concentrations per kilogram bodyweight. Regarding claim 14, Hodous on p. 28, l. 7-19 contemplates pharmaceutical compositions and includes solid preparations including soft capsules (l. 18). Regarding claim 16, Hodous on p. 30, l. 6-7 discusses single daily dosage. However, Hodous on the same page, l. 11-12 states “This dosage regimen may be adjusted to provide the optimal therapeutic response.” Therefore, one of ordinary skill would find it obvious to modify the single daily dose to be administered twice daily. Additionally, this modification, even without the teaching of Hodous, would be obvious to one of ordinary skill in the art as modifying doses and dose forms are within the skillset of one of ordinary skill. Regarding claim 17, Hodous on p. 3, l. 21-23 states “What is needed, therefore, are irreversible kinase inhibitors that covalently bind to their target polypeptide(s) without (substantially) binding to off-target polypeptides and, thereby, exerting undesirable off-target effects.” Hodous continues on the same page stating “The present invention provides a series of novel pyrimidine and pyridine kinase inhibitors. In some embodiments said kinase inhibitors are irreversible inhibitors of tyrosine kinases. In preferred embodiments, said irreversible kinase inhibitors inhibit BTK. While it is not intended that the compounds described by the present invention be limited to any specific mechanism of action, in some embodiments said irreversible kinase inhibitors exert a physiological effect by forming a covalent bond with Cys 481 in BTK.” Regarding claim 20, in addition to the discussion of the indefinite rejection above, the effect of “achieves a normal level of cell proliferation” is a result of administering the compound A225. Essentially, the limitation is an intrinsic property of administering A225. Therefore, the claim is obvious in view of the teachings of Hodous. Where Hodous contemplates acute myeloid leukemia, the art in Rushworth further affirms the decision for one of ordinary skill in the art to apply the A225 compound to treat acute myeloid leukemia as Rushworth teaches that Bruton’s tyrosine kinase (BTK) is a therapeutic target in acute myeloid leukemia (title). Rushworth in sec. Introduction states “Tyrosine kinases (TK) are attractive druggable targets in cancer. In [acute myeloid leukemia], TK-activating mutations occur in 50% of patients. Furthermore TK-dependent cell survival pathways are dysregulated in most cases. Bruton’s TK (BTK) has been identified as functionally important in malignant hematopoietic cells.” Rushworth on p. 1231, Figure 2 gives data showing BTK inhibition in AML cells via administration of the compound ibrutinib. Rushworth on p. 1232, Figure 3 provides evidence that ibrutinib inhibits AML proliferation. Therefore, one of ordinary skill in the art would find it obvious to administer compound A225 to treat AML as Hodous teaches that compound A225 has efficacy as a BTK inhibitor and Rushworth teaches BTK inhibition affects AML cell proliferation. Therefore, it would have been prima facie obvious at the time of the effective filing date for one of ordinary skill in the art to have taken the teachings of Hodous to arrive at the instant claims. One of ordinary skill in the art would further find it obvious to combine Hodous with Rushworth to arrive at the instant claims. One of ordinary skill would find motivation to make the combination as a Rushworth teaches BTK inhibition has a direct effect on AML cell proliferation. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. U.S. Patent 9,073,947 Claims 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-8 of U.S. Patent No. 9,073,947 in view of Hodous (cited above) and Rushworth (cited above). U.S. Patent 9,580,449 Claims 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-8 of U.S. Patent No. 9,580,449 in view of Hodous (cited above) and Rushworth (cited above). U.S. Patent 10,413,562 Claims 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-8 of U.S. Patent No. 10,413,562 in view of Hodous (cited above) and Rushworth (cited above). The reference patents above are drawn to compounds which include the A225 compound taught by Hodous. Reference claim 6 of U.S. Patent ‘449 actually lists compound A225. Where the patented claims teach the genus, Hodous teaches the specific compound. Rushworth then teaches reasoning to apply the compound to treat AML. U.S. Patent 11,491,153 Claims 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-23 of U.S. Patent No. 10,413,562 in view of Hodous (cited above) and Rushworth (cited above). The reference claims are drawn to a method of treating a myeloproliferative disorder, which includes acute myeloid leukemia. Compound A225 is included in the reference method 1, l. 4-6. Hodous and Rushworth teach administration of compound A225 to treat acute myeloid leukemia, which is a specific species within the genus of myeloproliferative disorders. Examiner’s Comments Additional discussion regarding inhibiting BTK to treat AML is found in Pillinger (Scientific Reports, 5:12949, 2015). A non-statutory double patenting rejection was considered over U.S. Patent 10,016,448 in view of Hodous and Rushworth above. The rejection was not made as the claims of the reference patent ‘448 are drawn to a method of rheumatoid arthritis, systemic lupus erythematosus, and other inflammatory diseases (see reference claim) which would be drawn to a different patient population. Conclusion No claims allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LUISALBERTO GONZALEZ whose telephone number is (571)272-1154. The examiner can normally be reached M-F 8:30-5:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached at (571) 272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LUISALBERTO GONZALEZ/Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Nov 20, 2024
Application Filed
Nov 02, 2026
Non-Final Rejection mailed — §103, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12760058
PRODRUGS OF NEUROACTIVE STEROIDS
4y 1m to grant Granted Oct 13, 2026
Patent 12708620
PRODRUGS AND MEDICAL USES THEREOF
5y 8m to grant Granted Aug 18, 2026
Patent 12708622
METHODS OF TREATING CANCER AND INHIBITING TYK2 AND MEK
3y 9m to grant Granted Aug 18, 2026
Patent 12698271
CRYSTALLINE FORM OF A SHP2 INHIBITOR
2y 10m to grant Granted Aug 04, 2026
Patent 12662481
SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS
4y 5m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
58%
Grant Probability
99%
With Interview (+47.6%)
2y 11m (~11m remaining)
Median Time to Grant
Low
PTA Risk
Based on 168 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month